NB: Concepts represent early planning stages for PAs, RFAs, or RFPs for Council 's input. Council approval does not guarantee that a concept will become an initiative.
If NIAID publishes an initiative from one of these concepts, we link to it below. For a full list of initiatives, go to NIAID Funding Opportunities.
Table of Contents
Non-human Primate Models to Evaluate Therapeutics
and Prevention Strategies for HIV
For the published initiative, see the May
10, 2007, solicitation, Non-Human Primate Models to Evaluate Therapeutic
Strategies and Topical Microbicides for HIV.
Request for Proposals
Contact: Anita Hughes
Phone: 301/496-0612
Email: anhughes@niaid.nih.gov
Objective: The purpose of this initiative is to provide the means
to evaluate therapeutic and topical microbicide interventions for the
treatment and prevention of HIV/AIDS in non-human primate animal
models.
Description: The proposed contract will support evaluation of
therapeutic and topical microbicide interventions
in a non-human primate model
utilizing SIV or SHIV. This will include: (1) in vitro assessment
of efficacy and toxicity of agents in non-human primate and human cells;
and (2) in vivo evaluation of efficacy and toxicity of agents
and strategies in animals. This resource will be preferentially used
for proof-of-concept
studies with the potential to advance development of the agent or strategy,
evaluations that cannot be done in other animal models of HIV infection,
optimization of candidates and interventions in an advanced stage of
development, confirmation of efficacy of candidates and interventions
that have proven
promising in other animal models, and model development. State-of-the-art
immunologic and virologic methodologies will be utilized for the quantitative
determination of viral load and relevant immune parameters.
Microbicide Innovation Program
For the published initiative, see the August 17, 2007, Guide announcement.
Request for Applications
Contact: Jim Turpin
Phone: 301/451-2732
Email: jturpin@niaid.nih.gov
Objective: The goal of the Microbicide Innovation Program (MIP)
is to establish an environment that fosters high risk-high reward development
activities.
Topical microbicide
discovery and development is typically viewed by the scientific community
as applied rather than innovative research. Frequently, a compound or
formulation may be unique, but the methods for determining its feasibility
as a microbicide may be routine or used in a manner requiring little
scientific innovation to implement. However, these standard methods or
approaches are critical for establishing feasibility and advancement
of the microbicide candidate into clinical evaluation. Program has recognized
the need to strengthen the pipeline by supporting hypothesis-driven development
that incorporates specific milestone-driven elements for determining
feasibility. To achieve this goal program staff have identified the R21/R33
mechanism to (1) assist applicants in the transition of innovative hypothesis-driven
projects to the development pipeline; (2) establish feasibility of microbicide
concepts; and (3) identify the most meritorious microbicide products
and analysis tools through a requisite milestone selection process. NIAID
will administer this mechanism in a budget neutral fashion.
Description: The purpose of the MIP is to support novel and
under-explored projects that have the potential to advance the field
of topical microbicides. The ultimate goal of the
MIP will be to strengthen and maintain an innovative microbicide pipeline
while facilitating the design, development, and transition of technologies
and methodologies to advance the field as a whole. The MIP will focus
on and encourage applications for: (1) discovery and exploration of microbicides
(singly or in combination) directed against HIV or HIV and sexually transmitted
infections linked to HIV acquisition; (2) emerging technologies
or models that contribute to the development of new and more efficient
ways of assessing microbicide safety, efficacy, and acceptability; and
(3) exploration of complex prevention strategies that incorporate vaginally
and/or rectally applied microbicides in the context of oral prophylaxis
and mucosal vaccines.
|
Subscribe to Alerts
